Immune Response Inc., Ocurest Laboratories Inc. deal

The companies signed a definitive reverse merger agreement under which privately held Ocurest will merge into IMMR. Terms were not disclosed. The combined company, which will keep the Ocurest name, will have 4.5 million shares outstanding on a fully diluted basis, following a one-for-1800 reverse split of IMMR's common shares. ...